HUMA
Humacyte Inc

7,791
Mkt Cap
$237.83M
Volume
2.4M
52W High
$6.77
52W Low
$1.09
PE Ratio
-5.32
HUMA Fundamentals
Price
$1.32
Prev Close
$1.27
Open
$1.27
50D MA
$1.50
Beta
1.93
Avg. Volume
5.08M
EPS (Annual)
-$1.26
P/B
-42.46
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Wall Street Analysts See Humacyte, Inc. (HUMA) as a Buy: Should You Invest?
According to the average brokerage recommendation (ABR), one should invest in Humacyte, Inc. (HUMA). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Zacks·6d ago
News Placeholder
More News
News Placeholder
Wall Street Analysts See Humacyte, Inc. (HUMA) as a Buy: Should You Invest?
According to the average brokerage recommendation (ABR), one should invest in Humacyte, Inc. (HUMA). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Zacks·6d ago
News Placeholder
Wall Street Analysts See Humacyte, Inc. (HUMA) as a Buy: Should You Invest?
According to the average brokerage recommendation (ABR), one should invest in Humacyte, Inc. (HUMA). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Zacks·6d ago
News Placeholder
Humacyte, Inc. (NASDAQ:HUMA) Receives Average Recommendation of "Moderate Buy" from Analysts
Shares of Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eight brokerages that are presently covering the company, Marketbeat...
MarketBeat·7d ago
News Placeholder
Humacyte, Inc. (NASDAQ:HUMA) Receives Average Recommendation of "Moderate Buy" from Analysts
Shares of Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eight brokerages that are presently covering the company, Marketbeat...
MarketBeat·7d ago
News Placeholder
Humacyte, Inc. (NASDAQ:HUMA) Receives Average Recommendation of "Moderate Buy" from Analysts
Shares of Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eight brokerages that are presently covering the company, Marketbeat...
MarketBeat·7d ago
News Placeholder
CenterBook Partners LP Buys 2,007,743 Shares of Humacyte, Inc. $HUMA
CenterBook Partners LP increased its stake in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 141.1% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange...
MarketBeat·18d ago
News Placeholder
Stock Traders Purchase Large Volume of Humacyte Put Options (NASDAQ:HUMA)
Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) saw unusually large options trading activity on Friday. Stock investors purchased 6,057 put options on the stock. This represents an increase of 114...
MarketBeat·19d ago
News Placeholder
Humacyte's (HUMA) Buy Rating Reaffirmed at BTIG Research
BTIG Research reaffirmed a "buy" rating and set a $6.00 price objective on shares of Humacyte in a report on Friday...
MarketBeat·19d ago
News Placeholder
D. Boral Capital Reiterates "Buy" Rating for Humacyte (NASDAQ:HUMA)
D. Boral Capital restated a "buy" rating and issued a $25.00 price objective on shares of Humacyte in a research note on Thursday...
MarketBeat·20d ago

Latest HUMA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.